AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Summary
- Prescient collaborating with the world-class cell therapy institute Peter MacCallum Cancer Centre to develop innovative cell therapy technologies, including CAR-T technologies.
- Prescient will own the resulting IP from the research program being undertaken by Peter Mac’s Professor Phil Darcy.
- PTX is the only ASX-listed healthcare player developing CAR-T programs, and this is a key strategic initiative for the Company to complement its Cell Therapy Enhancement programs.
ASX-listed clinical-stage company Prescient Therapeutics Limited (ASX:PTX) is well-known for developing breakthrough targeted and personalised medicines approaches for the treatment of challenging cancer.
On 14 August 2020, Prescient stock zoomed up by 6.667% to A$0.064 at AEST 2:12 PM after the Company announced a research collaboration with the world-class cell therapy institute Peter MacCallum Cancer Centre (Peter Mac) for developing innovative cell therapy technologies, including CAR-T technologies.
Under the terms of this research agreement, Prescient will own the IP (intellectual property) generated from the research program being led by Professor Phil Darcy of Peter Mac.
Melbourne-based Peter MacCallum Cancer Centre is an internationally recognised research and clinical leader in developing new therapies for cancer.
This is the second addition to the Cell Therapy Enhancement (CTE) Programs of Prescient Therapeutics. Prescient is already working with Carina Biotech and University of Adelaide on other CTE approaches.
Complementing the CTE programs, Prescient is also developing next-generation CAR-T therapies with its OmniCAR platform, following it announcement in late May 2020 that Prescient obtained key licenses from the University of Pennsylvania and Oxford University.
To Know More, Do Read: Impressive! Prescient Obtains Key Licenses for Next-Generation Immunotherapy Platform
Currently, Prescient Therapeutics is conducting a Share Purchase Plan (SPP) at 5.5c which closes on 20 August 2020 at AEST 5:00 PM. Click here to request personalised SPP forms.
Cell Therapy Enhancements Programs of Prescient
CAR-T is a cellular therapy that reprograms the immune cells of a cancer patient to identify and destroy cancer.
The research program, being undertaken in Professor Darcy’s laboratory at Melbourne-based Peter Mac, is an important addition to the Cell Therapy Enhancements (CTE) programs in the pipeline of Prescient.
On the same lines as the Cell Therapy Enhancements program that is underway with Carina Biotech, this research program aims to produce technologies complementing current CAR-T approaches.
The objective of Prescient’s CTE program is to develop efficacy as well as efficiency improvements that are relevant to 3rd parties in the cell therapy field (called CAR-T), which may incorporate these into their own programs under license.
Also Read: Get Acquainted with Prescient Therapeutics’ Next Generation Immunotherapy Platform
It is noteworthy to mention that Prescient will retain its previously built intellectual property and look to extend this portfolio by collaborating with world-renowned cancer centre Peter Mac.
Prescient Therapeutics CEO Steven Yatomi-Clarke stated that PTX is the only ASX-listed healthcare company developing CAR-T programs, and this is an important strategic initiative to complement programs of the Company in Cell Therapy Enhancements.
He also added-
Bottomline
Prescient has been progressing well in its cell therapy platform by obtaining two major licenses for developing innovative universal CAR Platform and now by collaborating with world-renowned Institute ‘Peter MacCallum Cancer Centre’. These developments drive Prescient to create innovative cell therapies for treating challenging cancers having unmet medical need.
These events demonstrate that Prescient Therapeutics is on a growth track backed by strong management in the most modern arena of cancer therapy.
